Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate (NYSE:CLVT) has announced a new $500 million share repurchase program for its outstanding ordinary shares, effective from January 1, 2025, through December 31, 2026. This program replaces the current one ending December 31, 2024, under which the company repurchased $300 million of shares, including $200 million in Q3-Q4 2024.
Additionally, Clarivate has prepaid $75 million of term-loan debt in Q4, bringing total 2024 prepayments to $133 million. The new buyback program, part of the company's Value Creation Plan, allows for open-market purchases through various methods, including Rule 10b5-1 trading plans, subject to market conditions and regulatory requirements.
Clarivate (NYSE: CLVT) has launched AI Search in Derwent™, an AI-powered patent search solution. The tool integrates AI with the Derwent World Patents Index (DWPI)™ to enhance innovation decision-making by delivering faster and more relevant patent search results. The AI Search leverages a language transformer model to understand context and retrieve pertinent results from over 160 million patent records. This solution aids patent researchers, attorneys, and IP professionals in conducting accurate first-pass patentability searches and validating results to ensure no relevant records are missed. DWPI, covering more than 120 million patents and over 62 million invention families, underpins the AI Search with manually written abstracts summarizing each invention's novelty and advantage. Gordon Samson, President of Intellectual Property at Clarivate, highlighted that this technology reduces the number of patents professionals need to review, thus speeding up and improving decision-making.
Clarivate and the Chinese Academy of Sciences have released their 11th annual Research Fronts 2024 report, identifying 125 dynamic research specialties in sciences and social sciences. The report highlights 110 'hot' and 15 'emerging' research fronts, including studies on monoclonal antibodies for early Alzheimer's treatment and Generative AI in education.
The analysis, based on Clarivate's Essential Science Indicators database, tracks patterns of co-citation among scientific papers. The accompanying comparative analysis shows the United States leading research activities across 11 areas, followed by Mainland China, with the UK, Germany, and France completing the top five countries.
Clarivate Plc (NYSE: CLVT) announced that Daikin Industries has selected IPfolio™ to optimize its intellectual property assets management. The leading air conditioner manufacturer will use this cloud-based solution to enhance operational efficiency, manage increasing IP filing volumes, and eliminate manual processes. IPfolio will be implemented across Daikin's global offices to facilitate collaboration through connected services and integrations. The solution's configurability will help Daikin meet its unique IP asset management needs while enabling more confident strategic decision-making and sustainable growth.
BioWorld, published by Clarivate (NYSE:CLVT), has launched 'Healing the Health Divide,' a seven-part series examining disparities in women's health research and funding. The series reveals that only 15% of venture capital funding in 2023 went to women's health-focused biopharma companies, while just 8% of funded companies included women's health assets. Key findings show that women's health deals since 2019 represent only 18.5% of all analyzed deals from 473 companies.
The series explores gender bias in research, untapped market potential, and efforts to improve diagnosis and treatment of conditions like endometriosis and cardiovascular disease, which disproportionately affect women.
Clarivate has unveiled its 2024 Highly Cited Researchers list, recognizing 6,636 influential researchers from over 1,200 institutions across 59 nations. The analysis reveals significant shifts in global research influence, with Mainland China and Hong Kong SAR gaining prominence while the U.S. share gradually decreases. The U.S. maintains leadership with 2,507 researchers (36.4%), while China follows with 1,405 researchers (20.4%). The Chinese Academy of Sciences leads institutions with 308 recognitions. The selection process has been enhanced with new filters to address publication manipulation and ensure research integrity.
Clarivate (NYSE:CLVT) and Healthcare Executive have released a report titled 'A Decade of Innovation, A Decade to Come,' analyzing Mainland China's transformation into a global biopharma powerhouse. The report highlights China's advancement to become one of the top three countries for initial drug launches, with its R&D expenditure growing 3.5 times over the past decade. Key developments include regulatory reforms, increased investment, and improved patient access to therapies. The National Reimbursement Drug List negotiations have reduced drug costs by 50-60%, while China's share of global licensing deals has increased from 6.5% to nearly 9% since 2015.
Clarivate (NYSE:CLVT) has announced the winners of its 2023 Healthcare Business Insights Revenue Cycle Awards, marking the program's 12th year. The awards recognize U.S. healthcare organizations for outstanding revenue cycle key performance indicators (KPIs), based on fiscal year data.
This year's recipients include Roper St. Francis Healthcare (Physician Group) from South Carolina, Bon Secours Mercy Health (Physician Group) from Ohio, Bronson Methodist Hospital from Michigan, and Roper St. Francis Healthcare from South Carolina. Winners demonstrated top decile performance across various financial metrics.
Clarivate (NYSE:CLVT) has released its fourth annual sustainability report, highlighting significant achievements in 2023. The company was recognized by Newsweek as one of 'America's Greatest Workplaces for Diversity' and 'America's Greenest Companies' for 2024. Notable milestones include 49% of revenue aligned with UN SDGs and partnerships with 53% of companies in the Dow Jones Sustainability World Index.
The company joined several UN initiatives and achieved an 80 score in the Human Rights Campaign's Corporate Equality Index. Employees contributed 23,242 volunteer hours through a 40-hour paid volunteer program. Clarivate's impact extends to supporting 95M+ patients in healthcare, 130M+ students, and 26K+ libraries, while working with 46 of the top 50 R&D companies globally.
Clarivate (NYSE:CLVT) has launched ProQuest One Sustainability, a comprehensive research solution designed to support sustainability curricula across research, teaching, and learning. The platform features over 1,500 scholarly journals, 40,000+ full-text case studies, and content from 37,000+ dissertations and theses.
The solution offers a transdisciplinary approach structured around sustainability's environmental, social, and economic pillars, aligned with the United Nations Sustainable Development Goals. It includes the AI-powered ProQuest Research Assistant to help users craft targeted searches and analyze documents effectively.
The platform covers important topics like climate change, renewable energy, environmental justice, and sustainable business practices, supporting Clarivate's commitment to sustainability and quality education.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?